Teva restructuring hits American HQ, claiming 200-plus Pennsylvania jobs

Teva is laying off 25% of its global workforce in an effort to cut $3 billion in annual costs.

Teva’s far-reaching cost cuts are hitting close to home—not just in Israel, but at its North American headquarters, too.

The embattled company is laying off more than 200 workers in and around its North Wales, Pennsylvania, home base, it said in a WARN notice filed with the Pennsylvania Department of Labor and Industry. Those layoffs are effective Friday.

Specifically, the generics giant has pink-slipped 65 employees across three buildings in Horsham, Pennsylvania, and North Wales, 96 across sites in Fraser and Great Valley, Pennsylvania, and 47 more at a West Chester, Pennsylvania, location.

Sept. 15-17,2020

Cytiva Virtual Event: Tapas & Tech Talks Copy - Strategies for robust and scalable

Strategies for robust and scalable processes: from research through late-stage trials
(with Cytiva and IQVIA)

RELATED: Teva's stunning list of cuts targets 14K jobs, $3B in costs and plants around the globe

The layoffs come as part of new Teva CEO Kåre Schult's plan to squeeze $3 billion from the company’s annual costs as it struggles under some serious dealmaking debt. In December, the company said it would pare down its workforce by 25%, shedding thousands more jobs than industry watchers expected.

The news did not go over well in Israel, which was tapped for 3,000 of the planned cuts. Government offices, banks, schools, health services, Israel’s main airport and more shut down as part of a nationwide strike, and key officials urged Schultz to shutter plants in Ireland to spare Israeli jobs. Ultimately, they secured a reprieve for 140 workers—but only a temporary one.

RELATED: Israel urges embattled Teva to close plants in Ireland to save jobs at home: report

In the U.S., meanwhile, Teva has said it intends to consolidate seven office locations under one roof, and the location of that main campus isn’t yet known, the Philadelphia Business Journal noted. That could mean a move for its North American headquarters.

“Those decisions are still being made,” a spokeswoman told the Journal.

Suggested Articles

After a slow start, Teva's Ajovy launch is improving following the FDA approval for an autoinjector.

After Trump's "Buy American" executive order for essential medicines, the pharma industry is pushing back.

The U.S. is slamming the brakes on its $765 million loan to Kodak amid insider trading allegations and questions about its fitness for the job.